A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment Combination of oral PL7737 and tirzepatide resulted in additive ...

Explore the implications of GLP-1 drugs in managing India's obesity crisis as experts warn of potential misuse and health ...

Researchers found that pairing tirzepatide with hormone therapy boosts weight loss success in postmenopausal women—up to 17% ...

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules ...

Where, How, and Why You Exercise Affects Mental Health: StudyPublished in Medicine and Science in Sports and Exercise, a recent study from the ...

WEIGHT loss jabs could boost men’s sex lives, a study suggests. Research found injections like Wegovy and Mounjaro can raise ...

Combining ASC47 with semaglutide, the new therapy aims to reshape obesity treatment with targeted, once-monthly injections.

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

Popular weight loss medications like Ozempic can help reverse low testosterone levels in men with obesity or Type 2 diabetes, according to new research ...